Needle Exchanges Report National Surge in Peptide Users
QuIHN and NUAA report a marked increase in peptide users at Australian needle exchanges, with one service now distributing four times its contracted quota.
Needle and syringe exchange services across Australia are reporting a “marked increase” in peptide users, with one organisation now distributing four times the volume of injecting equipment it is contracted to supply.
The ABC reported on 6 August that harm reduction services are increasingly concerned the rise in unapproved peptide use could leave them without enough supply for at-risk drug users.
A national trend, not a local issue
Geoff Davey, chief executive of the Queensland Injectors Health Network (QuIHN), said there had been a “marked increase” in peptide users at needle exchange facilities since last year.
“November, December, it seemed to spike. It’s not just a local issue, it’s a trend we’re seeing nationally,” Mr Davey told the ABC.
He described a diverse group of people accessing services for peptide use, citing weight loss, image enhancement, and body wellbeing as reported motivations.
“We’re also seeing acute presentations into emergency departments, such as liver toxicity,” he said, referring to six cases in Victoria that were linked to the unapproved peptide retatrutide.
Services strained beyond contracted capacity
In New South Wales, the Needle Users and AIDS Association (NUAA) said demand was outstripping its funded capacity.
Chief executive Mary Harrod described the trend as “incredibly worrying” and characterised unregulated peptide use as “a giant lab experiment that’s happening in real time, with no real response”.
“We’re contracted to distribute 500,000 units [of needles and syringes] and we’re up to two million. We can’t keep up with that demand,” Ms Harrod said. She added that meeting demand would require the organisation to let go of two or three employees.
Experts quoted by the ABC said they were glad some peptide users were seeking health advice through harm reduction services, but remained concerned about those who were not.
Unverifiable product quality
Rebecca Lang, chief executive of the Queensland Network of Alcohol and other Drug Agencies (QNADA), pointed to the risks of an unregulated supply chain.
“In an unregulated market, you can’t be sure that what it says on the label is what’s in the container,” she said.
The concern echoes findings reported in June, when laboratory testing commissioned by Australian media found an unapproved retatrutide product at roughly double its advertised strength.
What this means for the regulatory picture
The reports add a public health dimension to a regulatory environment already under strain. Unapproved injectable peptides are advertised widely on social media and sold through channels including Facebook Marketplace and postal delivery, as the ABC documented earlier in August.
For researchers and buyers, the practical implications are threefold: products sourced from unapproved channels may not match their labels, purchasing without a prescription is an offence under state and territory poisons legislation, and growing demand for injecting equipment is stretching services whose first priority is preventing blood-borne virus transmission among people who inject drugs.
What to watch
Whether the demand trend continues will depend on supply-side enforcement and the pace of regulatory attention to online peptide marketing. The ABC’s reporting indicates harm reduction services are now raising capacity concerns with public health authorities, which may feed into state and federal policy discussions in coming months.
Sources
- ABC News: “Marked increase” in peptide users using needle exchange facilities around Australia (6 August 2026)
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.